Novel NTRK3 Fusions in Fibrosarcomas of Adults

NTRK fusions in malignant tumors are therapeutic targets of tyrosine kinase inhibitors. Because they occur only in a small subset of mesenchymal tumors, knowledge regarding the corresponding histology is important to effectively identify patients who could benefit from targeted therapy. In this study, using RNA sequencing, we identified novel NTRK3 fusions involving related partner genes in 2 adult bone and soft tissue tumors that met the current histologic criteria of fibrosarcoma. Case 1 involved the left radius of a 38-year-old woman, whereas in case 2, the right thigh of a 26-year-old man was affected. Histologically, both tumors consisted of the long fascicular growth of long spindle cells. The tumor in case 1 additionally showed focal myxoid changes. Tumor cells had nonpleomorphic, atypical nuclei, and lacked evidence of a specific line of differentiation. Both tumors showed widespread CD34 immunoreactivity and very limited expression of actin. RNA sequencing detected in-frame fusion transcripts of STRN (exon 3)-NTRK3 (exon 14) in case 1 and STRN3 (exon 3)-NTRK3 (exon 14) in case 2, which were confirmed by reverse transcription polymerase chain reaction and Sanger sequencing. Pan-TRK immunostaining was diffusely positive in both cases. Fluorescence in situ hybridization showed signal patterns compatible with NTRK3 rearrangements in both cases, with case 2 additionally harboring a CDKN2A homozygous deletion. This study expands the clinicopathologic and genetic spectrum of sarcomas associated with NTRK fusions, and suggests that CD34-positive fibrosarcoma of bone and soft tissue could be a good candidate for NTRK testing.

[1]  C. Fletcher,et al.  Evaluation of pan‐TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis‐like neural tumour and histological mimics , 2018, Histopathology.

[2]  T. Royce,et al.  A novel case of an aggressive superficial spindle cell sarcoma in an adult resembling fibrosarcomatous dermatofibrosarcoma protuberans and harboring an EML4‐NTRK3 fusion , 2018, Journal of cutaneous pathology.

[3]  Hong Yang,et al.  Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis , 2018, The American journal of surgical pathology.

[4]  C. Antonescu,et al.  Dermatofibrosarcoma protuberans with a novel COL6A3‐PDGFD fusion gene and apparent predilection for breast , 2018, Genes, chromosomes & cancer.

[5]  Jessica L. Davis,et al.  Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors , 2018, The American journal of surgical pathology.

[6]  J. Blay,et al.  Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions , 2018, Modern Pathology.

[7]  M. Ladanyi,et al.  NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma , 2018, The American journal of surgical pathology.

[8]  Jessica L. Davis,et al.  Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. , 2018, The Lancet. Oncology.

[9]  O. Delattre,et al.  Transcriptomic definition of molecular subgroups of small round cell sarcomas , 2018, The Journal of pathology.

[10]  M. Harris,et al.  Recurrent EML4–NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy , 2018, Modern Pathology.

[11]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[12]  H. Mano,et al.  Pediatric soft tissue tumor of the upper arm with LMNA-NTRK1 fusion. , 2018, Human pathology.

[13]  Jessica L. Davis,et al.  Infantile NTRK-associated Mesenchymal Tumors , 2018, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[14]  M. Ladanyi,et al.  Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions , 2017, The American journal of surgical pathology.

[15]  P. Stephens,et al.  Identification of NTRK fusions in pediatric mesenchymal tumors , 2017, Pediatric blood & cancer.

[16]  F. Meric-Bernstam,et al.  Targeting TRK family proteins in cancer , 2017, Pharmacology & therapeutics.

[17]  Narasimhan P. Agaram,et al.  Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors , 2016, The American journal of surgical pathology.

[18]  Y. Oda,et al.  ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours , 2016, Histopathology.

[19]  S. Wiemann,et al.  Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern , 2016, The Journal of pathology.

[20]  A. D. Dei Tos,et al.  Transcriptome sequencing identifies ETV6–NTRK3 as a gene fusion involved in GIST , 2016, The Journal of pathology.

[21]  A. Sartore-Bianchi,et al.  NTRK gene fusions as novel targets of cancer therapy across multiple tumour types , 2016, ESMO Open.

[22]  P. Stephens,et al.  Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib. , 2016, Journal of the National Cancer Institute.

[23]  Dara L Aisner,et al.  An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. , 2015, Cancer discovery.

[24]  S. Miyamoto,et al.  p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer. , 2015, American journal of clinical pathology.

[25]  P. Stephens,et al.  Comprehensive genomic profiling of sarcomas from 267 adolescents and young adults to reveal a spectrum of targetable genomic alterations. , 2015 .

[26]  R. Doebele,et al.  TRKing down an old oncogene in a new era of targeted therapy. , 2015, Cancer discovery.

[27]  H. Asamura,et al.  STAT6 Immunohistochemistry Is Helpful in the Diagnosis of Solitary Fibrous Tumors , 2014, The American journal of surgical pathology.

[28]  M. Nikiforova,et al.  ETV6‐NTRK3 is a common chromosomal rearrangement in radiation‐associated thyroid cancer , 2014, Cancer.

[29]  Pengyuan Liu,et al.  Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer , 2014, Proceedings of the National Academy of Sciences.

[30]  R. Bernards,et al.  Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing , 2013, The Journal of pathology.

[31]  R. Sciot,et al.  Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches , 2012, Virchows Archiv.

[32]  A. Grigoriadis,et al.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.

[33]  A. Folpe,et al.  Adult-type Fibrosarcoma: A Reevaluation of 163 Putative Cases Diagnosed at a Single Institution Over a 48-year Period , 2010, The American journal of surgical pathology.

[34]  T. Hansen,et al.  Low‐grade fibrosarcoma—report on 39 not otherwise specified cases and comparison with defined low‐grade fibrosarcoma types , 2006, Histopathology.

[35]  E. van Marck,et al.  Desmoplastic fibroma of bone: an immunohistochemical study including beta-catenin expression and mutational analysis for beta-catenin. , 2005, Human pathology.

[36]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .

[37]  A. Nakagawara,et al.  Trk receptor tyrosine kinases: a bridge between cancer and neural development. , 2001, Cancer letters.

[38]  T. Ishida,et al.  Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues. , 2001, American journal of clinical pathology.

[39]  P. Sorensen,et al.  The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells , 2000, Oncogene.